This protocol covers first-line management of acute myeloid leukemia in patients aged 55 and above who carry an FLT3 mutation at diagnosis — a subgroup where mutation status directly shapes the recommended therapeutic approach.
Newly diagnosed acute myeloid leukemia in an older adult (aged ≥55 years) with a confirmed FLT3 mutation. This combination of age and mutation status defines the population for this protocol and informs therapy selection beyond standard antileukemic approaches.
Evidence supports antileukemic therapy in combination with an FLT3 inhibitor, rather than antileukemic therapy alone. The specific agents, combinations, and sequencing vary by patient factors — the complete regimen options and selection criteria are available in the full protocol.
The primary clinical aim is to increase the rate of complete remission (CR) or CR with incomplete hematologic recovery (CR/CRi).
DOI: 10.1182/bloodadvances.2025017934
For older adults with newly diagnosed AML who have an FLT3 mutation, the ASH guideline panel suggests ALT in combination with an FLT3 inhibitor over ALT alone (conditional recommendation based on low certainty in the evidence of effects ⨁⨁◯◯).
View source ↗